In the SURPASS-2 trial, patients with obesity and T2D who received tirzeapatide (5 mg weekly) achieved greater HbA1c and body weight reductions than those receiving semaglutide (1 mg weekly) during the 40 week study (64) despite comparable putative GLP-1R occupancy at these doses (47). The gene discussed is GLP1R; the disease is Obesity.